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Abstract 
Aims: To report the clinical and diagnostic findings of a patient with Acanthamoeba 
keratitis resistant to both polyhexamethylene biguanide (PHMB)-hexamidine and 
chlorhexidine-hexamidine treatment.  
Methods: Slit-lamp biomicroscopy, corneal cell scraping and histopathology were 
performed on a 39-year-old woman presenting with corneal ulcer in her left eye.  
Results: The patient was successfully treated with PHMB-chlorhexidine association 
therapy. Subsequent perforating keratoplasty remained clear at the last follow-up visit 
after 7 months and increased visual acuity to 20/20 with correction.  
Conclusions: This case emphasizes the proteiform aspects of Acanthamoeba drug 
resistance, and suggests that PHMB-chlorhexidine association might represent an 
additional option for cases resistant to standard therapy. 
 
Introduction 
Acanthamoeba keratitis is a chronic infection caused by free-living amoebas, which is 
primarily related to contact lens use. It typically presents as a corneal ring infiltrate 
associated with severe pain. The infection is commonly misdiagnosed for non-infectious 
or bacterial, fungal or viral keratitis, as it happened in this case. A provisional diagnosis 
may be done based upon clinical presentation; however, definitive diagnosis requires 
histology, culture, and/or identification of Acanthamoeba nucleic acid by polymerase 
chain reaction [1]. Treatment of Acanthamoeba keratitis is based on the association of a 
biguanide (polyhexamethylene or chlorhexidine) with a diamidine (hexamidine or 
propamidine) [2–12]. Acanthamoeba keratitis is estimated to affect 1 per 250,000 people 
in the United States; although rates vary among studies: from 1.65–2.01 per million in the 
general population to 1 per 10,000 in contact lens users [2]. Case Rep Ophthalmol 2011;2:338–342 
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Case Report 
A 39-year-old woman was admitted to the Cornea Unit of the San Raffaele Hospital for consultation 
concerning infectious keratitis in her left eye (OS). Visual acuity was counting fingers at 1 m. Ocular 
history was positive for mild myopia in OO (–1 sph), soft contact lens use, and fresh water exposure 
while wearing lenses. One month before, she had visited her ophthalmologist due to pain in her OS, and 
an epithelial defect was noticed. She had previously been treated with antibiotic-steroid association eye 
drops. After an initial improvement, the symptoms had returned, and when we visited her she 
complained of severe pain, especially in her OS.  
On observation of the OS, we noticed a ring infiltrate that was more evident on the inferior half of 
the cornea, which stained with fluorescein, and perikeratic hyperemia. The anterior chamber and the 
pupil were normal, and the crystalline lens was transparent (fig. 1, panel 1). Examination of the right 
eye was unremarkable. We performed cornea scraping, which stained positive for calcofluor white 
confirming an Acanthamoeba infection and started therapy with polyhexamethylene biguanide (PHMB) 
0.02% and hexamidine 0.1% every 1 h. The treatment was tapered down to PHMB and hexamidine 
every 2 h after 5 days and subsequently to 4 times per day. 
After 3 months, the patient did not show further improvement. Visual acuity was stable at counting 
fingers at approximately 1 m, the cornea infiltrate was denser and corneal edema had appeared in the 
central cornea (fig. 1, panel 2). Corneal scraping was re-performed yielding a positive result for 
Acanthamoeba.  
The patient was then started on hexamidine and chlorhexidine every 1 h. After 2 months, the ulcer 
still showed no sign of improvement. Visual acuity did not improve (counting fingers at 1 m), the eye 
was inflamed, the infiltrate was thicker and stained with fluorescein, and the epithelium was irregular 
(fig. 1, panel 3). A third corneal scraping was carried out, which was again positive for Acanthamoeba. 
Treatment was then switched to PHMB and chlorhexidine every 2 h for 2 months, which was 
gradually tapered over the following 4 months. At this point, natural visual acuity had improved to 
20/100 (20/40 with pinhole), and the patient reported a significant reduction of pain. The eye showed 
reduced inflammation, the infiltrate had become a leucoma with neovessels and the epithelium was 
stable (fig. 1, panel 4). Corneal débridement has been shown to increase drug penetration in 
Acanthamoeba keratitis [13], and this has possibly contributed to the treatment efficacy. However, since 
we performed a corneal scraping before any treatment changes, we think that the better efficacy of the 
last treatment (i.e. double-biguanide) is confirmed. There were no ocular signs of active infection and 
anti-amoebic therapy was suspended. Eight months after therapy was stopped, no signs of recurrent 
infection could be detected, and the patient referred no pain. We hence proposed penetrating 
keratoplasty to improve vision. The removed cornea was Acanthamoeba-free at histopathology 
examination (calcofluor white stain). The last reportable visit, 7 months after penetrating keratoplasty, 
revealed a clear corneal graft and no recurrence of the infection (fig. 1, panel 5); visual acuity was 20/40 
with –4.5 sph and –4 cyl at 110, and reached 20/20 with contact lenses. 
Discussion 
Treatment of Acanthamoeba keratitis is based on the association of a biguanide 
(PHMB or chlorhexidine, 0.02% solution) with a diamidine (hexamidine or propamidine, 
0.1% solution) [2–12] and should be carried out for weeks or months, or even longer [5, 
8]. The development of drug resistance has been described during treatment [6, 14, 15]. 
Higher drug concentrations up to 0.06% for PHMB and up to 0.2% for chlorhexidine 
have been proposed in therapeutic regimens, including those in association with oral 
ketoconazole and topical steroids [16].  
Some authors suggest that even biguanide monotherapy may be effective [17]. 
However, to the best of our best knowledge, there has been no report of Acanthamoeba 
keratitis improvement with the association of two biguanide agents.  Case Rep Ophthalmol 2011;2:338–342 
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In this case, we started treatment with a biguanide-diamidine association. The 
infection did not improve even when we changed biguanide (chlorhexidine instead of 
PHMB). The infection finally responded to the PHMB-chlorhexidine association therapy. 
This led to the healing of the ulcer and prompted us to subsequently perform penetrating 
keratoplasty, after which visual acuity reached 20/40 with correction. 
We therefore suggest that double-biguanide topical treatment might be an option in 
cases of Acanthamoeba keratitis that are resistant to standard biguanide-diamidine 
association therapy. 
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Fig. 1. Slit-lamp picture of the evolution of Acanthamoeba keratitis. Panel 1: cornea at the first visit. 
Note the ring infiltrate. Panel 2: corneal infiltrate did not improve following a PHMB-desomedine 
regimen every 1 h after 3 months. Panel 3: the corneal ulcer showed no signs of improvement at 2 
months after therapy switch to hexamidine and chlorhexidine every 1 h. Panel 4: the corneal ulcer 
finally receded, leaving a vascularized leucoma 4 months following combined double-biguanide 
PHMB-chlorhexidine treatment. Note that the conjunctival hyperemia has also resolved. Panel 5: 
perforating corneal graft remained transparent 7 months after transplantation and no sign of 
recurrence was observed. 
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